Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), Myrna Nahas, Salvia Jain(Broad Institute), Adam Morin(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Matthew Weinstock(Beth Israel Deaconess Medical Center), Jessica Liegel(Beth Israel Deaconess Medical Center), Marzia Capelletti(Caris Life Sciences (United States))
Transplantation and Cellular Therapy
January 23, 2020
10.1016/j.bbmt.2019.12.396
Cited by 3

Related Papers

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
|Cancer Cell|2010|1.1k